Zhonghua Zhong Liu Za Zhi. 2023 Dec 23;45(12):1018-1031. doi: 10.3760/cma.j.cn112152-20230427-00186.
Breast cancer is the most common malignant tumor in women around the world, and it is also a common cause of death in female patients with malignant tumors in China, which seriously harms women's health. At present, with the application of comprehensive treatment approaches, breast cancer has become one of the most effective solid tumors. Platinum drugs are widely used in malignant tumors, and they are also commonly used as effective chemotherapeutic drugs for breast cancer. To regulate the application of platinum drugs in breast cancer, the experts from Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association, discuss and approve the "Guidelines for clinical application of platinum drugs in breast cancer (2023 edition)" . This guideline is developed from the "Expert consensus on the clinical application of platinums in advanced breast cancer (2020 version)" , which is updated from the latest evidence based on breast cancer at home and abroad, for platinum drugs in breast cancer clinical use, application scheme, efficacy analysis and treatment of adverse effects. This guideline aims to guide clinicians to use drugs rationally, and to further standardize the diagnosis and treatment.
乳腺癌是全球女性最常见的恶性肿瘤，也是我国女性恶性肿瘤患者常见的死亡原因之一，严重危害女性健康。目前，随着综合治疗方法的应用，乳腺癌已成为最有效的实体瘤之一。铂类药物广泛应用于恶性肿瘤，也是乳腺癌常用的有效化疗药物。为规范铂类药物在乳腺癌中的应用，中国医师协会肿瘤医师分会乳腺癌学组专家讨论并通过了《乳腺癌铂类药物临床应用指南（2023年版）》。本指南是在《晚期乳腺癌铂类临床应用专家共识（2020年版）》的基础上，根据国内外乳腺癌最新循证证据更新而成，涉及铂类药物在乳腺癌临床使用中的应用方案、疗效分析及不良反应处理等内容。本指南旨在指导临床医生合理用药，进一步规范诊疗行为。
